PEA Quercetin Cholecalciferol Composition for CKD Progression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for chronic kidney disease (CKD) are inadequate in slowing disease progression and often come with side effects, and there is a need for alternative strategies that can effectively manage inflammation and Klotho under-expression without adverse effects.
Innovation Solution
A pharmaceutical composition comprising a synergistic combination of Palmitoylethanolamide (PEA), Quercetin, and Cholecalciferol, which works to improve or prevent CKD progression by enhancing renal function and reducing inflammation and Klotho deficiency, formulated to avoid synthetic FAAH inhibitor side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional pharmacotherapy is used to treat CKD, then disease progression may be slowed, but side effects occur
Solution Approach 1:
The patent changes the therapeutic parameters by using natural compounds (PEA, quercetin, cholecalciferol) at specific dosage ranges instead of conventional pharmaceuticals, aiming to achieve therapeutic effects while avoiding synthetic drug side effects
Solution Approach 2:
The patent combines multiple natural compounds (PEA, quercetin, and cholecalciferol) in a composite formulation to achieve synergistic effects for treating CKD, potentially improving efficacy while maintaining safety
2Manufacturing precision
If dietary therapy is used when renal function drops to 20-30%, then serum creatinine may normalize, but renal failure still progresses
Solution Approach 1:
The patent applies therapeutic intervention at earlier stages of CKD (when renal function is 20-30%) to prevent progression to renal failure, rather than waiting until creatinine normalization is achieved through dietary therapy alone
3Object-generated harmful factors
If dialysis is initiated when renal function reaches 5-10%, then uremia can be managed, but quality of life decreases and mortality risk remains high
Solution Approach 1:
The patent aims to prevent CKD progression to the stage requiring dialysis by implementing therapeutic intervention at earlier stages, thereby avoiding the harmful effects of dialysis and reducing mortality risk
Solution Approach 2:
The patent converts the harmful accumulation of uremic toxins into a beneficial situation by using natural compounds that reduce inflammation and address Klotho deficiency, thereby preventing toxin accumulation in the first place
4Reliability
If inflammation is not controlled in CKD, then disease progression accelerates, but conventional anti-inflammatory drugs have side effects
Solution Approach 1:
The patent changes the approach to inflammation control by using natural compounds (PEA and quercetin) with anti-inflammatory properties instead of conventional anti-inflammatory drugs, aiming to reduce inflammation without associated side effects
5Reliability
If Klotho deficiency is not addressed in CKD, then extra-renal complications develop, but current treatments do not effectively increase Klotho levels
Solution Approach 1:
The patent changes the therapeutic approach by using cholecalciferol (vitamin D3) to address Klotho deficiency, leveraging the relationship between vitamin D and Klotho expression to prevent extra-renal complications
Data Source
Figure 1~2
Figure 3~4
AI summary
The present application relates to a pharmaceutical composition/formulation for improving or preventing progression of chronic kidney disease (CKD) caused due to inflammation and/or Klotho under expression. More particularly, the invention relates to a composition/formulation comprising a synergistic combination of Palmitoylethanolamide (PEA), Cholecalciferol and one or more natural ingredients. The invention also provides various formulations and methods of preparing the same.